Peter J. Piliero

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

Jacob Lalezari, Keith Henry, Mary O’Hearn et al. · New England Journal of Medicine · 2003 · 915 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacotherapy +16

HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy

David B. Clifford, Constantin T. Yiannoutsos, Marcie A. Glicksman et al. · Neurology · 1999 · 248 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects

Ian Sanne, Peter J. Piliero, Kathleen Squires et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2003 · 224 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

Mark Nelson, Keikawus Arastéh, Bonaventura Clotet et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 151 citations

Pharmacy, Internal Medicine, Pharmacotherapy +17

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

Jacob Lalezari, Melanie Thompson, Priny Kumar et al. · AIDS · 2005 · 111 citations

Medicine, Pharmacokinetics, Pharmacology +17